Ipamorelin Research: Mechanism, Key Studies & the Newest Data
Before the details
Ipamorelin research breaks into a few clean buckets. It works by switching on the ghrelin receptor (called GHS-R1a) on the pituitary gland, which triggers a short burst of growth hormone. The defining finding, from 1998, is that it does this without raising cortisol or prolactin, unlike the older peptides in its class [1]. The human data are thin: one pharmacokinetics study mapped a roughly 2-hour half-life [2], and one efficacy trial for slow bowel recovery after surgery failed [3]. Animal studies show real effects on bone growth [4] and body weight [5]. The newest work, from 2024 and 2026, mostly reviews and contextualizes ipamorelin rather than adding big new human results [16][18]. Below, each major finding gets its own section with the numbers and the source.
The mechanism: a selective ghrelin-receptor agonist
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) on pituitary somatotrophs, the cells that store and release growth hormone [1]. Receptor activation runs through the Gq/PLC pathway, raising intracellular calcium and triggering a growth-hormone pulse. This route is distinct from, and complementary to, the GHRH pathway (which works through cAMP), which is the mechanistic basis for pairing ipamorelin with a GHRH analog such as CJC-1295 [9]. Beyond the pituitary, GHS-R1a signaling reaches enteric and vagal neurons (affecting gut motility) and, in preclinical work, pancreatic islet cells, giving a direct insulin-releasing effect [12].
The founding selectivity dataset (1998)
The study that named ipamorelin remains the cornerstone. Raun and colleagues showed in 1998 that ipamorelin released growth hormone potently in primary rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 of 2.3 nmol/kg, comparable to GHRP-6's 3.9 nmol/kg [1]. The defining result was the absence of off-target endocrine activity: no significant ACTH or cortisol elevation above the GHRH baseline even at doses more than 200-fold above the growth-hormone ED50 [1]. That established ipamorelin as the first highly growth-hormone-selective secretagogue. The characterization was acute, single-exposure, not a chronic-dosing study, which matters when interpreting long-term claims.
Human pharmacokinetics: a ~2-hour half-life and a single pulse (1999)
The clearest human dataset is pharmacokinetic. Population PK/PD modeling in healthy male volunteers (eight per dose level; five 15-minute IV infusions of 4.21 to 140.45 nmol/kg) showed dose-proportional, linear kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response was a single discrete pulse peaking at about 0.67 hours (40 minutes) after dosing [2]. This is one of the only human ipamorelin datasets in existence and the source of every half-life figure on this site.
The Phase 2 efficacy trial that missed (2014)
The defining human efficacy anchor is a negative result. In a prospective, randomized, controlled proof-of-concept study (NCT00672074), 114 adults undergoing bowel resection received ipamorelin at 0.03 mg/kg IV twice daily for up to seven days [3]. The primary endpoint, time to first tolerated meal, was not met: 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15) [3]. Treatment-emergent adverse events were comparable between arms (87.5% ipamorelin vs 94.8% placebo), indicating no ipamorelin-specific safety signal in that short perioperative window, but efficacy was simply not demonstrated [3]. No Phase 3 program followed.
Bone growth and body-composition signals in animals
The animal efficacy data are more encouraging and more numerous. Subcutaneous ipamorelin at 18, 90, and 450 microg/day (divided three times daily for 15 days) dose-dependently increased the longitudinal bone-growth rate of adult female Sprague-Dawley rats from 42 microm/day (vehicle) to 44, 50, and 52 microm/day, with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers, indicating a partly local, growth-hormone-pulse-driven skeletal effect [4]. The most recent in-vivo experiment, a 2024 ferret study, found that intraperitoneal ipamorelin at 1 to 3 mg/kg inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase, with no anti-emetic effect [5].
Ipamorelin cjc-1295
The popular ipamorelin cjc-1295 pairing rests on complementary pharmacology, not on a combination trial. CJC-1295 is a long-acting GHRH analog: pulsatile growth-hormone secretion persisted during continuous stimulation by CJC-1295, showing that sustained GHRH-pathway activation does not abolish the physiologic growth-hormone rhythm [9], and CJC-1295 produces durable IGF-1 elevation [10]. The rationale is to combine a steady GHRH signal (CJC-1295) with a pulsatile ghrelin-receptor signal (ipamorelin) acting through a different pathway [1]. A 2026 USC narrative review reported the combination improved maximum tetanic tension in a steroid-induced muscle-loss model in mice, while emphasizing the evidence is animal-only [15]. An observational report in hypogonadal men found combined GHS therapy raised serum IGF-1, illustrating real biological activity under off-label, non-trial use [11]. No controlled human trial of the combination for any outcome exists.
What is cjc 1295 ipamorelin
"CJC-1295 ipamorelin" refers to a two-peptide research combination, not a single drug. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor to drive sustained growth-hormone output and durable IGF-1 elevation [10]. Ipamorelin is a separate selective ghrelin-receptor (GHS-R1a) agonist that adds a pulsatile growth-hormone release through a different pathway [1]. Combined, the two are studied as complementary GH-axis stimulators [9]. The combination itself has never been tested in a controlled human trial, so all combination claims are extrapolated from each peptide's single-agent pharmacology [3].
The newest reviews (2026) and where the class sits
The 2026 literature is largely synthesis. A peptide-therapy review in sports medicine reviewed ipamorelin as an investigational growth-hormone-axis secretagogue with preclinical metabolic and tissue-repair signals, emphasizing the absence of rigorous human trials and the potential for serious harm [16]. A structured narrative review in sports medicine categorized it as a growth-hormone-axis peptide with no reproducible human evidence for musculoskeletal outcomes and recommended confining use to research protocols [18]. A doping review noted its short half-life creates analytical challenges for detection and flagged insulin resistance and cardiovascular strain as class risks [7]. Within gastroenterology, ipamorelin's GI rationale is situated alongside more clinically advanced ghrelin agonists like relamorelin [8]. The consistent message: an interesting, well-characterized mechanism still waiting on human outcome data.